Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B
OwnerDan T. Stinchcomb, James McSwiggen +1inventors
InventorsDan T. Stinchcomb, James McSwiggen, Kenneth G. Draper
Life of this patent
Estimating the term…
Abstract
The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, allozymes and antisense, which modulate the expression or function of NFKB genes, such as REL-A, REL-B, REL (c-rel), NFKB1 (p105/p50) and NFKB2 (p100)/p52/p49).
Claims94
An enzymatic nucleic acid molecule which down regulates expression of a sequence encoding a subunit of NFKB, wherein said enzymatic nucleic acid molecule is in an Inozyme, Zinzyme, G-cleaver, or Amberzyme configuration.
An enzymatic nucleic acid molecule comprising a sequence selected from the group consisting of SEQ ID NOs. 711-1420, 1717-2012, 2151-2656, 2994-3626, and 3770-3917.
An enzymatic nucleic acid molecule comprising at least one binding arm wherein one or more of said binding arms comprises a sequence complementary to a sequence selected from the group consisting of SEQ ID NOs. 1-30, 32-48, 50-108, 100-136, 138-183, 185-306, 308-450, 452-497, 499-710, 1421-1428, 1430-1454, 1456-1464, 1466-1475, 1477-1482, 1484-1501, 1504-1535, 1537-1543, 1545-1548, 1550-1563, 1565-1575, 1578-1586, 1588-1601, 1603-1607, 1609-1716, 2013-2015, 2017-2056, 2058-2064, 2066-2076, 2078-2082, 2084, 2086-2150, 2657-2993, and 3627-3769.
An antisense nucleic acid molecule comprising a sequence complementary to a sequence selected from the group consisting of SEQ ID NOs. 1-710, 1421-1716, 2013-2150, 2657-2993, and 3627-3769.
Dependencies are inferred from the claim text.